Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 11/20 | 0.45 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.45 |
| ▸ | GABRA1 | P14867 | 10/20 | 0.45 |
| ▸ | GABRA5 | P31644 | 10/20 | 0.45 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.45 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.45 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.45 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.45 |
| ▸ | GABRP | O00591 | 1/20 | 0.45 |
| ▸ | GABRD | O14764 | 1/20 | 0.45 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.45 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.45 |
| ▸ | GABRE | P78334 | 1/20 | 0.45 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.45 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.45 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29563011 | 0.81 | GABRG2 (0.46) | GABRG2GABRB3GABRA1GABRA5GABRA3 | |
| SCHEMBL163615 | 0.81 | GABRG2 (0.46) | ALDH1A1GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL13105640 | 0.81 | GABRG2 (0.46) | GABRG2GABRB3GABRA1GABRA5GABRA3 | |
| SCHEMBL3700486 | 0.81 | GABRG2 (0.46) | GABRG2GABRB3GABRA1GABRA5GABRA3 | |
| SCHEMBL177762 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTL3MBTL1KDM4CNPC1 | |
| SCHEMBL30142073 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTL3MBTL1KDM4CNPC1 | |
| SCHEMBL28133307 | 0.81 | ALDH1A1 (0.57) | ALDH1A1MAPTL3MBTL1KDM4CNPC1 | |
| SCHEMBL15114586 | 0.80 | KDM4E (0.56) | ALDH1A1GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL3882564 | 0.80 | GABRG2 (0.45) | GABRG2GABRB3GABRA1GABRA5GABRA3 | |
| SCHEMBL9979936 | 0.80 | GABRG2 (0.56) | GABRG2GABRB3GABRA1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| CN-119841776-A | Tyrosine kinase inhibitors and uses thereof | 华上生技医药股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| WO-2025021218-A1 | CYSTAL FORM OF PROPENONE-CONTAINING BIOLOGICAL INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-119371440-A | Salt containing acrylketone biological inhibitor, salt crystal form, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-118574831-A | Biological inhibitor containing acrylketone, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-08-30 | — | — | CN | disclosed |
| EP-4405359-A2 | MDM2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| EP-4259605-A1 | 4-(2-FLUORO-4-METHOXY-5-3-(((1-METHYLCYCLOBUTYL)METHYL)CARBAMOYL)BICYCLO[2.2.1]HEPTAN-2-YL)CARBAMOYL)PHENOXY)-1-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID DERIVATIVES AND SIMILAR COMPOUNDS AS RXFP1 MODULATORS FOR THE TREATMENT OF HEART FAILURE | Astrazeneca AB (SE) | 2023-10-18 | — | — | EP | disclosed |
| CN-116547270-A | 4- (2-fluoro-4-methoxy-5-3- (((1-methylcyclobutyl) methyl) carbamoyl) bicyclo [2.2.1] hept-2-yl) carbamoyl) phenoxy) -1-methylcyclohexane-1-carboxylic acid derivatives and similar compounds as RXFP1 modulators for the treatment of heart failure | 阿斯利康(瑞典)有限公司 | 2023-08-04 | — | — | CN | disclosed |
| WO-2023143514-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2023-08-03 | — | — | WO | disclosed |
| EP-1631567-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005116028-A2 | BICYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-10-27 | — | — | US | disclosed |
| WO-2005032548-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS INHIBITORS OF RAF KINASE | CHIRON CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| WO-2005016918-A2 | HETEROCYCLIC N-ARYL CARBOXAMIDES AS CYTOKINE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-1499311-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | Chiron Corporation (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040186114-A1 | Cytokine inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-09-23 | — | — | US | disclosed |
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-06-24 | — | — | US | disclosed |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | NOVARTIS AG (CH) | 2004-05-06 | — | — | US | disclosed |
| WO-2003082272-A1 | SUBSTITUTED BENZAZOLES AND USE THEREOF AS RAF KINASE INHIBITORS | CHIRON CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122237-A1 | Substituted benzazoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | ALDH1A1 1216/4885MAPT 3948/4885L3MBTL1 1929/4885 |
| US-20040087626-A1 | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase | BRAF, RAF1, ARAF | ALDH1A1 1008/4885MAPT 3981/4885L3MBTL1 2178/4885 |
| US-20040186114-A1 | Cytokine inhibitors | IL1A, IL1B, IL1R1 | ALDH1A1 896/4885MAPT 4440/4885L3MBTL1 4296/4885 |
| US-20050239820-A1 | Bicyclic heterocycles as kinase inhibitors | CDK2, ABL1, CDKN1A | ALDH1A1 2213/4885MAPT 3582/4885L3MBTL1 3107/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | ALDH1A1 1531/4885MAPT 4858/4885L3MBTL1 872/4885 |
| US-20250152564-A1 | PROPYLENE KETONE-CONTAINING BIOINHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | CYP51A1, HSD17B7, CYP46A1 | ALDH1A1 522/4885MAPT 4016/4885L3MBTL1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.